MedTrace Logo

Product Transference Study of Testagen™ TDS®-Testosterone

NCT02733133 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2024-11-20

No results posted yet for this study

Summary

This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has been applied and the potential of product to raise serum androgen levels in those women.

Conditions

  • Hypogonadotropism

Interventions

DRUG

Testagen® TDS Testosterone 5% HypoSpray®

Topically applied Testosterone Hormone Replacement Lotion

Sponsors & Collaborators

  • Advanced Therapies Centre, The London Clinic

    collaborator OTHER

  • Transdermal Delivery Solutions Corp

    lead INDUSTRY

Principal Investigators

  • Shern L. Chew, M.D., Ph.D. · Consultant Physician and Professor of Endocrine Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2025-10-31
Completion
2025-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02733133 on ClinicalTrials.gov